Amgen Inc. (BIT:1AMGN)

Market Cap	131.40B
Revenue (ttm)	29.73B
Net Income (ttm)	5.64B
Shares Out	n/a
EPS (ttm)	10.41
PE Ratio	23.31
Forward PE	13.84
Dividend	6.30 (2.55%)
Ex-Dividend Date	May 15, 2025

Volume	60
Average Volume	172
Open	246.50
Previous Close	245.05
Day's Range	246.50 - 247.30
52-Week Range	233.00 - 312.85
Beta	n/a
RSI	41.80
Earnings Date	Aug 4, 2025

About Ligand Pharmaceuticals

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.